Free cash flow · 2019–2025
Beam Therapeutics free cash flow
−$360M−$3.9M · FY2025
Beam Therapeutics (BEAM) reported −$360M in free cash flow for fiscal 2025, −$3.9M from the year before.
| Fiscal year | Free cash flow | Change | Filing |
|---|---|---|---|
| FY2025 | −$360M | −$3.9M | Derived |
| FY2024 | −$356M | −$173M | Derived |
| FY2023 | −$183M | −$157M | Derived |
| FY2022 | −$26.4M | +$86.7M | Derived |
| FY2021 | −$113M | −$981,000 | Derived |
| FY2020 | −$112M | −$27.6M | Derived |
| FY2019 | −$84.5M | — | Derived |
Free cash flow — Free cash flow is operating cash flow minus capital expenditure: what is left once the company has paid to maintain and expand its asset base. We calculate it from two lines in the same filing, and a company is only ranked here if it reported both.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026
Calculated from two reported figures, so it has no single filing of its own.
Free cash flow at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Beam Therapeutics free cash flow |url=https://companiesranked.com/en/company/beam-therapeutics/free-cash-flow |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Beam Therapeutics free cash flow. CompaniesRanked. https://companiesranked.com/en/company/beam-therapeutics/free-cash-flowBibTeX
@misc{companiesranked-en-company-beam-therapeutics-free-cash-flow-2026,
author = {{CompaniesRanked}},
title = {{Beam Therapeutics free cash flow}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/beam-therapeutics/free-cash-flow}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.